Antares Pharma Inc.

4.04-0.0300-0.74%Vol 356.71K1Y Perf 52.26%
Apr 13th, 2021 16:00 DELAYED
BID4.02 ASK4.17
Open4.09 Previous Close4.07
Pre-Market- After-Market4.04
 - -  - -%
Target Price
6.42 
Analyst Rating
Strong Buy 1.00
Potential %
58.91 
Finscreener Ranking
★★★★★     59.08
Insiders Trans % 3/6/12 mo.
-100/-87/-87 
Value Ranking
★★★★     56.98
Insiders Value % 3/6/12 mo.
-100/-98/-98 
Growth Ranking
★★★★★     82.83
Insiders Shares Cnt. % 3/6/12 mo.
-100/-96/-96 
Income Ranking
 —    -
Market Cap679.37M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
61.57 
Earnings Date
4th May 2021

Today's Price Range

4.024.10

52W Range

2.395.07

5 Year PE Ratio Range

-65.00-11.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-1.46%
1 Month
-11.01%
3 Months
-6.91%
6 Months
20.78%
1 Year
52.26%
3 Years
73.39%
5 Years
343.96%
10 Years
144.85%

TickerPriceChg.Chg.%
ATRS4.04-0.0300-0.74
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
1.60
2.00
0.20
0.39
3.60
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
57.80
9.20
10.90
-16.50
52.07
RevenueValueIndustryS&P 500US Markets
116.52M
0.69
44.16
26.62
Earnings HistoryEstimateReportedSurprise %
Q04 20200.040.03-25.00
Q03 20200.030.030.00
Q02 2020-0.010.01200.00
Q01 20200.00-0.01-
Q04 20190.000.03-
Q03 2019-0.020.01150.00
Q02 2019-0.04-0.0175.00
Q01 2019-0.04-0.0325.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.02-50.00Negative
6/2021 QR0.04-20.00Negative
12/2021 FY0.14-44.00Negative
12/2022 FY0.27-12.90Negative
Next Report Date4th May 2021
Estimated EPS Next Report0.02
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume356.71K
Shares Outstanding168.16M
Trades Count2.54K
Dollar Volume7.62M
Avg. Volume1.28M
Avg. Weekly Volume531.47K
Avg. Monthly Volume840.60K
Avg. Quarterly Volume1.26M

Antares Pharma Inc. (NASDAQ: ATRS) stock closed at 4.04 per share at the end of the most recent trading day (a -0.74% change compared to the prior day closing price) with a volume of 356.78K shares and market capitalization of 679.37M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 178 people. Antares Pharma Inc. CEO is Robert F. Apple.

The one-year performance of Antares Pharma Inc. stock is 52.26%, while year-to-date (YTD) performance is 1.25%. ATRS stock has a five-year performance of 343.96%. Its 52-week range is between 2.39 and 5.07, which gives ATRS stock a 52-week price range ratio of 61.57%

Antares Pharma Inc. currently has a PE ratio of 12.50, a price-to-book (PB) ratio of 5.82, a price-to-sale (PS) ratio of 5.87, a price to cashflow ratio of 32.90, a PEG ratio of 2.32, a ROA of 31.48%, a ROC of 12.29% and a ROE of 62.99%. The company’s profit margin is 52.07%, its EBITDA margin is 10.90%, and its revenue ttm is $116.52 Million , which makes it $0.69 revenue per share.

Of the last four earnings reports from Antares Pharma Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.02 for the next earnings report. Antares Pharma Inc.’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for Antares Pharma Inc. is Strong Buy (1), with a target price of $6.42, which is +58.91% compared to the current price. The earnings rating for Antares Pharma Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Antares Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Antares Pharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.19, ATR14 : 0.23, CCI20 : -67.88, Chaikin Money Flow : -0.10, MACD : -0.10, Money Flow Index : 41.11, ROC : -0.25, RSI : 43.53, STOCH (14,3) : 37.84, STOCH RSI : 0.66, UO : 40.36, Williams %R : -62.16), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Antares Pharma Inc. in the last 12-months were: Anton G. Gueth (Option Excercise at a value of $231 958), Fred M. Powell (Buy at a value of $46 740), Leonard S. Jacob (Option Excercise at a value of $34 319), Leonard S. Jacob (Sold 15 321 shares of value $77 371 ), Peter J. Graham (Option Excercise at a value of $50 400), Peter J. Graham (Sold 45 000 shares of value $221 650 ), Robert F. Apple (Option Excercise at a value of $470 210), Robert F. Apple (Sold 587 460 shares of value $2 913 603 ), Thomas J. Garrity (Option Excercise at a value of $212 800), Thomas J. Garrity (Sold 170 000 shares of value $728 900 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Antares Pharma Inc.

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

CEO: Robert F. Apple

Telephone: +1 609 359-3020

Address: 100 Princeton South, Ewing 08628, NJ, US

Number of employees: 178

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

59%41%

Bearish Bullish

67%33%

News

Stocktwits